Fungal infections Flashcards

1
Q

Who gets fungal infections?

A

○ Patients with an impaired immune system​
- Patients with primary immunodeficiencies​
- Patients with HIV/AIDS​
- Patients with malignancies (neutropenia) & transplants​
- Premature neonates (immature immune system)​
○ Affecting patients with chronic lung diseases (pulmonary aspergillosis and other moulds)​
- Asthma​
- Cystic Fibrosis​
- Chronic obstructive lung disorders​
○ Affecting patients in ICU settings​

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What is the aetiology of Mucocutaneus candidiasis?

A
○ Antibiotic use​
○ Moist areas​
○ Inhalation steroids​
○ Neonates < 3 months​
○ Presenting symptom of primary immunodeficiency
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Which primary immunodeficiency disorders charecteristics can Mucocutaneuous candiditis be a presenting symptom of?

A
  • Neutropenia​
  • Low CD4+ T-cells​
  • impaired IL-17 immunity​
    □ AD-Hyper IgE syndrome​
    ® Deficit of IL-17 producing cells​
    □ Dectin-1 deficiency​
    ® Reduced levels of IL-17​
    □ CARD9 deficiency​
    ® Low proportion of circulating IL-17 T-cells​
    □ APECED syndrome​
    ® High titers of neutralizing Ab against IL-17A, IL-17F and/or IL-22​
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What is the mortality of invasive canditis?

A

40%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Where does invasive canditis commune?

A

The gut

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What are the additional risk factors for a invasive canditis infection?

A
  • Broad-spectrum antibiotics​
  • Intravascular catheters​
  • Total parenteral nutrition​
  • Abdominal surgery​
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

How is an invasive canditis infection diagnosed?

A
  • Blood culture or culture from normally sterile site​
  • β-d-glucan high NPV and performs very well to exclude invasive candidiasis​
  • Recent developments in PCR assays very promising​
  • In infants and children performance lower due to sampling issues
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

How are Aspergillus and Aspergillosis transmitted?

A
  • sporulation​
  • hydrophobic conidia​
  • diameter 2-3 µm​
  • airborne / inhalation​
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Who gets acute invasive pulmonary aspergillosis?

A

® Neutropenic patients (incidence 1-10%)​
® Post transplants: stem cell > solid organ (incidence up to 8%)​
® Patients with defects in phagocytes​

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What haens in acute invasive pulmonary aspergillosis?

A

® Rapid and extensive hyphal growth​
® Thrombosis and haemorrhage​
® Angio-invasive and dissemination​
® Absent or non-specific clinical signs and symptoms​
® Persistent febrile neutropenia despite broad-spectrum antibiotics​
® Mortality rates around 50% (but depending on immune recovery)​

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Who gets (sub) acute Invasive Pulmonary Aspergillosis?

A

Non-neutropenic host (graft-versus-host disease, neutrophil disorders)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What happens in (sub) acute Invasive Pulmonary Aspergillosis?

A
® Non-angioinvasive​
® Limited fungal growth​
® Pyogranulomatous infiltrates​
® Tissue necrosis​
® Excessive inflammation​
® Non-specific clinical signs and symptoms​
® Mild to moderate systemic illness
® Mortality 20-50%​
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

How long does one have to have pulmonary aspergillosis for it to be classified as chronic?

A

> 3 months

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Who gets chronic pulmonary aspergillosis?

A

Patients with underlying chronic lung conditions

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What happens in chronic pulmonary aspergillosis?

A

® Pulmonary exacerbations (not responding to antibiotics)​
® Lung function decline​
® Increased respiratory symptoms as cough, decreased exercise tolerance and dyspnoea​
® Positive sputum cultures for Aspergillus​
◊ 50% of CF patients are infected​
® High morbidity but causative mortality rates less clear​

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Who gets allegic aspergillosis?

A

® Allergic bronchopulmonary aspergillosis in CF and asthma (incidence 10-15%)​
® Asthma or CF with fungal sensitisation (incidence 5-15%)​

17
Q

What happens in allegic aspergillosis?

A

® immunological responses to a variety of A. fumigatus​ antigens in the CF-host (10-15%) result in:​
◊ Acute/subacute deterioration of lung function and respiratory symptoms​
◊ New abnormalities chest imaging​
◊ Elevated immunoglobulin E (IgE) level​
◊ Increased Aspergillus specific IgE or positive skin-test​
◊ Positive Aspergillus specific IgG​

18
Q

What is Pulmonary aspergilloma?

A

A fungal mass that usually frows in lung cavities

19
Q

When do you get Pulmonary aspergilloma?

A
  • Sarcoidosis​
  • Bronchiectasis​
  • Bronchial cysts and bullae​
  • After pulmonary infections​
20
Q

How is pulmonary aspergillosis diagnosed in non-neutropenic patients?

A

□ Cultures of sputum and/or bronchoalveolar lavage, and/or biopsy​
□ Aspergillus specific IgG and IgE in chronic and allergic pulmonary aspergillosis​

21
Q

How is pulmonary aspergillosis diagnosed in neutropenic patients?

A

□ High resolution CT-chest​
® ‘halo-sign’ and ‘air-crescent sign’​
□ Molecular markers in blood: galactomannan and PCR-Aspergillus (high NPV and are suited for screening purposes)​
□ BAL and biopsies if clinical condition allows​

22
Q

How can Cryptococcus and Cryptococcosis

be tranmitted?

A

Inhalation

23
Q

Where can Cryptococcus and Cryptococcosis

be found?

A

bark of a variety of trees, bird faeces and organic matter

24
Q

What happens in Cryptococcus and Cryptococcosis infections?

A

○ Pulmonary infection from asymptomatic to pneumonia​
○ Dissemination to brain: meningoencephalitis in HIV/AIDS patients (CD4 < 100 cells/ul)​
○ Clinical presentation: headache, confusion, altered behaviour, visual disturbances, coma (due to raised intracranial pressure in 60-80%)​

25
Q

How is Cryptococcus and Cryptococcosis diagnosed?

A
  • Cerebrospinal fluid: Indian Ink preparation (80% sensitivity), culture, high protein and low glucose, Cryptococcus antigen (lateral flow assay)​
  • Blood: culture, Cryptococcus antigen​
26
Q

What are the outcomes of Cryptococcus and Cryptococcosis?

A
  • Africa: 3-month mortality 70%​
  • US: 3-months mortality 25%​
  • Factors associated with mortality:​
    □ Delay in presentation and diagnosis​
    □ Lack of access to antifungals​
    □ Inadequate induction therapy​
    □ Delays in starting antiretroviral therapy​
    □ Immune reconstitution syndrome​
27
Q

What are the antifungal agents to treat infections?

A
○ Amphotericin B formulations (iv)​
- Acting on ergosterol > lysis​
○ Azoles (iv, oral)​
- Inhibiting ergosterol synthesis​
○ Echinocandins (iv)​
- Inhibiting glucan synthesis​
○ Flucytosine (iv, oral)​
- Inhibiting fungal DNA synthesis​